Indaptus Therapeutics, Inc. (INDP): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of INDP were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No INDP insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
INDP short interest
Low short interest. 0.9% of INDP shares are sold short: about 1 share in 117. Over the last 12 reports the number of shares short went up 1795%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.14M INDP shares were sold short, 0.9% of the shares outstanding, up 33.0% from the report before. At the average daily volume of 287,809 shares, buying them all back would take about 4.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.14M | 0.86% | +33% | 287,809 | 4.0 |
| Oct 15, 2026 | 856,708 | 0.64% | +4% | 497,322 | 1.7 |
| Sep 30, 2026 | 822,250 | 0.62% | -10% | 794,918 | 1.0 |
| Sep 15, 2026 | 916,352 | 0.69% | +332% | 2.31M | 1.0 |
| Aug 31, 2026 | 212,357 | 0.16% | +72% | 1.46M | 1.0 |
| Aug 14, 2026 | 123,737 | 0.09% | +33% | 136,608 | 1.0 |
| Jul 31, 2026 | 93,141 | 4.15% | -64% | 88,009 | 1.1 |
| Jul 15, 2026 | 259,720 | 11.58% | +89% | 75,877 | 3.4 |
| Jun 30, 2026 | 137,594 | 6.14% | -72% | 239,554 | 1.0 |
| Jun 15, 2026 | 493,245 | 22.00% | +2768% | 5.16M | 1.0 |
| May 29, 2026 | 17,200 | 0.77% | -71% | 132,680 | 1.0 |
| May 15, 2026 | 60,118 | 2.68% | -15% | 64,118 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Indaptus Therapeutics company events
Indaptus Therapeutics filed 20 reports on Form 8-K in the last 12 months, 11 of them about an important change (leadership, control). The latest was on Oct 20, 2026.
- Oct 20, 2026AnnouncementThe Company completed the Private Placement, having received the full purchase price from each of the Purchasers in accordance with the terms of the Purchase Agreement, as amended. Filing
- Sep 30, 2026AgreementAs previously disclosed in the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. with the Securities and Exchange Commission on September 9, 2026, on September 8, 2026, the Company entered into a Stock Purchase Agreement with the purchasers party thereto, pursuant to which the Company… Filing
- Sep 10, 2026AgreementIndaptus Therapeutics, Inc. entered into a Stock Purchase Agreement with the purchasers party thereto, pursuant to which the Company agreed to issue and sell to the Purchasers, in a private placement, an aggregate of 20,338,974 shares of the Company’s common stock, par value $0.01 per share, for… Filing
- Sep 8, 2026AgreementAmended an earlier report. Indaptus Therapeutics, Inc. entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co., LLC, which amends and restates in its entirety, and supersedes and replaces, the At The Market Offering Agreement, dated June 1, 2022, between the Company and Wainwright. Filing
- Sep 4, 2026LeadershipTim Ruan notified the Board of Directors of Indaptus Therapeutics, Inc. of his resignation from the Board, effective immediately. Filing
- Sep 1, 2026AgreementIndaptus Therapeutics, Inc. entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co., LLC, which amends and restates in its entirety, and supersedes and replaces, the At The Market Offering Agreement, dated June 1, 2022, between the Company and Wainwright. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 24, 2026AgreementIndaptus Therapeutics, Inc. entered into a Stock Purchase Agreement with certain non-U.S. accredited investors named therein, pursuant to which the Company agreed to issue and sell an aggregate of 20,000,000 shares of its common stock, par value $0.01 per share, at a purchase price of $0.60 per… Filing
- Jun 5, 2026LeadershipMr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors of Indaptus Therapeutics, Inc. Filing
- May 15, 2026ResultsReleased financial results. Filing
- Apr 24, 2026LeadershipAmended an earlier report. The Board of Directors of Indaptus Therapeutics, Inc. appointed Mr. Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors of the Board, effective April 22, 2026. Filing
- Apr 23, 2026LeadershipThe Board of Directors of Indaptus Therapeutics, Inc. appointed Mr. Tim Ruan and Dr. Yi Zhang as independent directors of the Board, effective April 22, 2026. Filing
- Apr 3, 2026LeadershipResignation of Officer Nir Sassi resigned as Chief Financial Officer on April 1, 2026. Filing
- Mar 24, 2026ControlAs described in Item 1.01 of the Current Report on Form 8-K filed by Indaptus Therapeutics, Inc. on December 23, 2025, on December 22, 2025, the Company entered into a Securities Purchase Agreement with David E. Lazar, pursuant to which he purchased from the Company 300,000 shares of Series AA… Filing
- Feb 27, 2026ControlAs described below under Item 5.07 of this Current Report on Form 8-K, at the Special Meeting, stockholders of the Company approved the issuance of common stock upon the conversion of the Preferred Stock. Filing
- Feb 12, 2026AgreementIndaptus Therapeutics, Inc. entered into warrant repricing agreements with certain holders of warrants to purchase an aggregate of 913,638 shares of common stock of the Company that were originally issued in financing rounds during 2024 and 2025 at exercise prices ranging from $8.30 to $47.60. Filing
- Jan 20, 2026LeadershipAs previously reported on December 22, 2025, in connection with the transactions contemplated by the securities purchase agreement with investor David E. Lazar, Indaptus Therapeutics, Inc. entered into employment modification agreements with, among others, Jeffrey A. Meckler, Co-Chief Executive… Filing
- Jan 8, 2026LeadershipThe Board of Directors of Indaptus Therapeutics, Inc. increased its size from eight to nine members and appointed David Natan to fill the vacancy. Filing
- Jan 2, 2026LeadershipMichael Newman, Mark Gilbert, and Anthony Maddaluna, members of the Board of Directors of Indaptus Therapeutics, Inc., each notified the Company of its resignation from the Board effective upon the approval of David Lazar’s nominees at the Company’s next stockholders’ meeting. Filing
- Dec 23, 2025LeadershipResignation of Directors Mr. Robert E. Martell and Ms. Hila Karah (together, the “Resigning Directors”) resigned on December 22, 2025 and December 23, 2025, respectively, following approval of the offering. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Indaptus Therapeutics financials
Famous investors that hold INDP
1 of the 50 well-known investors we track reported holding INDP in their latest 13F filing. The largest position is Israel Englander's, worth $166K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 72,073 | $166K | 0.0% | +522% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named INDP in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 22, 2026 | Dai Junyi | 13D/A | 7.3% |
| Oct 22, 2026 | Yao Yun | 13D/A | 27.3% |
| Oct 22, 2026 | Dai Junyi | 13D/A | 7.3% |
| Oct 22, 2026 | Sino Lion Ventures Ltd | 13D/A | 25.3% |
| Oct 22, 2026 | Sino Lion Ventures Ltd | 13D/A | 25.3% |
| Oct 22, 2026 | Yao Yun | 13D/A | 27.3% |
| Oct 21, 2026 | Yang Ting | 13D/A | 6.5% |
| Oct 21, 2026 | Yang Ting | 13D/A | 6.5% |
Questions about Indaptus Therapeutics, Inc. (INDP) stock
Are INDP insiders buying or selling?
No INDP insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in INDP?
As of Oct 30, 2026, 1.14M INDP shares were sold short, 0.9% of the shares outstanding, up 33.0% from the report before. At the average daily volume of 287,809 shares, buying them all back would take about 4.0 trading days (days to cover). See the history.
Which famous investors hold INDP?
1 of the 50 well-known investors we track reported INDP in their latest 13F filing, including Israel Englander. The largest position is worth $166K. See all holders.
Executive pay
Indaptus Therapeutics's chief executive was paid a total of $2.2M for the year ended Dec 31, 2025, up 90% from $1.2M the year before. In the last 12 months, Indaptus Therapeutics's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.